{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:29:14Z","timestamp":1791944954426,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K01 AG068365"],"award-info":[{"award-number":["K01 AG068365"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR072577"],"award-info":[{"award-number":["P30AR072577"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Osteoarthritis (OA) patients taking prescription opioids for pain are at increased risk of fall or fracture, and the concomitant use of interacting drugs may further increase the risk of these events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To identify prescription opioid\u2010related medication combinations associated with fall or fracture.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials &amp; Methods<\/jats:title><jats:p>We conducted a case\u2010crossover\u2010based screening of two administrative claims databases spanning 2003 through 2021. OA patients were aged 40\u2009years or older with at least 365\u2009days of continuous enrollment and 90\u2009days of continuous prescription opioid use before their first eligible fall or fracture event. The primary analysis quantified the odds ratio (OR) between fall and non\u2010opioid medications dispensed in the 90\u2009days before the fall date after adjustment for prescription opioid dosage and confounding using a case\u2010time\u2010control design. A secondary analogous analysis evaluated medications associated with fracture. The false discovery rate (FDR) was used to account for multiple testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 41\u2009693 OA patients who experienced a fall and 24\u2009891 OA patients who experienced a fracture after at least 90\u2009days of continuous opioid therapy. Top non\u2010opioid medications by ascending p\u2010value with OR\u2009&gt;\u20091 for fall were meloxicam (OR 1.22, FDR\u2009=\u20090.08), metoprolol (OR 1.06, FDR\u2009&gt;0.99), and celecoxib (OR 1.13, FDR\u2009&gt;\u20090.99). Top non\u2010opioid medications for fracture were losartan (OR 1.20, FDR\u2009=\u20090.80), alprazolam (OR 1.14, FDR\u2009&gt;\u20090.99), and duloxetine (OR 1.12, FDR\u2009=\u20090.97).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Clinicians may seek to monitor patients who are co\u2010prescribed drugs that act on the central nervous system, especially in individuals with OA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5773","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:55:04Z","timestamp":1709182504000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Risk of fall or fracture with concomitant use of prescription opioids and other medications in osteoarthritis patients"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-6671","authenticated-orcid":false,"given":"Nazleen F.","family":"Khan","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-5412","authenticated-orcid":false,"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Katz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Department of Medicine Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Orthopedics Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-8996","authenticated-orcid":false,"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Biostatistics Harvard T.H. Chan School of Public Health  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seanna M.","family":"Vine","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2517-3579","authenticated-orcid":false,"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Department of Medicine Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23933"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.019"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.32584"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glaa038"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532\u20105415.2011.03318.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g6380"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220216"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2314"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010013\u20102777\u20108"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223\u2010012\u20109603\u20108"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268\u2010017\u20100207\u20107"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1376"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.21.1.193"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000904"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115853"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22721"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.03.012"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"e_1_2_10_20_1","unstructured":"Utah Medicaid Services.Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors.https:\/\/medicaid.utah.gov\/Documents\/files\/Opioid-Morphine-EQ-Conversion-Factors.pdf"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.277"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1112772"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110531"},{"issue":"9","key":"e_1_2_10_24_1","first-page":"1","article-title":"Drugs Most frequently involved in drug overdose deaths: United States, 2011\u20102016","volume":"67","author":"Hedegaard H","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_2_10_26_1","unstructured":"US Food and Drug Administration.FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.https:\/\/www.fda.gov\/media\/99761\/download"},{"key":"e_1_2_10_27_1","unstructured":"US Food and Drug Administration.FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin Gralise Horizant) and pregabalin (Lyrica Lyrica CR) when used with CNS depressants or in patients with lung problems.https:\/\/www.fda.gov\/media\/133681\/download"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.10.004"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glx229"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T06:43:29Z","timestamp":1710571409000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/pds.5773"],"URL":"https:\/\/doi.org\/10.1002\/pds.5773","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"2023-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5773"}}